Mylan Speciality Lp patents expiration
1. Accuneb patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6702997 | MYLAN SPECIALITY LP | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
Dec, 2021
(2 years ago) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 30 April, 2001
Treatment: Indicated for the relief of bronchospasm in patients 2-12 years of age with asthma (reversible obstructive airway disease)
Dosage: SOLUTION;INHALATION
ACCUNEB family patents
2. Aerospan Hfa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5980867 | MYLAN SPECIALITY LP | Flunisolide aerosol formulations |
Dec, 2013
(10 years ago) | |
| US5776433 | MYLAN SPECIALITY LP | Flunisolide aerosol formulations |
Jul, 2015
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Aug 28, 2016 |
Drugs and Companies using FLUNISOLIDE ingredient
Market Authorisation Date: 27 January, 2006
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
AEROSPAN HFA family patents
3. Astepro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9919050 | MYLAN SPECIALITY LP | Compositions comprising azelastine |
Nov, 2025
(1 year, 6 months from now) | |
| US8518919 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(1 year, 6 months from now) | |
| US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2011 |
| New Patient Population(NPP) | Aug 30, 2016 |
| M(M-129) | Aug 30, 2016 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents
4. Duoneb patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6632842 | MYLAN SPECIALITY LP | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
Dec, 2021
(2 years ago) | |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 21 March, 2001
Treatment: Treatment of bronchospasm associated with copd in patients requiring more than one broncho dilator
Dosage: SOLUTION;INHALATION
DUONEB family patents
5. Dymista patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9901585 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(10 months ago) | |
| US9259428 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(10 months ago) | |
| US8163723 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2023
(7 months ago) | |
|
US9259428 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Dec, 2023
(4 months ago) | |
|
US8163723 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2024
(a month ago) | |
| US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(1 year, 10 months from now) | |
|
US8168620 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 20, 2018 |
| Pediatric Exclusivity(PED) | Aug 20, 2018 |
| New Combination(NC) | May 01, 2015 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: Treatment of seasonal allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis
Dosage: SPRAY, METERED;NASAL
DYMISTA family patents
6. Edluar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6761910 | MYLAN SPECIALITY LP | Pharmaceutical composition for the treatment of acute disorders |
Sep, 2019
(4 years ago) | |
| US8512747 | MYLAN SPECIALITY LP | Pharmaceutical composition for the treatment of acute disorders |
Sep, 2019
(4 years ago) | |
| US9597281 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Apr, 2027
(2 years from now) | |
| US9265720 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Feb, 2031
(6 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 13 March, 2009
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET;SUBLINGUAL
EDLUAR family patents
7. Elestrin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7470433 | MYLAN SPECIALITY LP | Formulations for transdermal or transmucosal application |
Aug, 2021
(2 years ago) | |
| US7198801 | MYLAN SPECIALITY LP | Formulations for transdermal or transmucosal application |
Jun, 2022
(1 year, 9 months ago) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 15 December, 2006
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
ELESTRIN family patents
8. Epipen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7449012 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(1 year, 4 months from now) | |
| US7794432 | MYLAN SPECIALITY LP | Automatic injector with kickback attenuation |
Sep, 2025
(1 year, 4 months from now) | |
| US9586010 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(1 year, 4 months from now) | |
| US8048035 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(1 year, 4 months from now) | |
| US8870827 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(1 year, 4 months from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 03 August, 1995
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
EPIPEN family patents
9. Epipen Jr. patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8048035 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(1 year, 4 months from now) | |
| US7449012 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(1 year, 4 months from now) | |
| US7794432 | MYLAN SPECIALITY LP | Automatic injector with kickback attenuation |
Sep, 2025
(1 year, 4 months from now) | |
| US8870827 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(1 year, 4 months from now) | |
| US9586010 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(1 year, 4 months from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 03 August, 1995
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
EPIPEN JR. family patents
10. Muse patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474535 | MYLAN SPECIALITY LP | Dosage and inserter for treatment of erectile dysfunction |
Dec, 2012
(11 years ago) | |
| US5886039 | MYLAN SPECIALITY LP | Method and composition for treating erectile dysfunction |
Mar, 2016
(8 years ago) | |
Drugs and Companies using ALPROSTADIL ingredient
Market Authorisation Date: 19 November, 1996
Treatment: Treatment of erectile dysfunction
Dosage: SUPPOSITORY;URETHRAL
MUSE family patents
11. Sfrowasa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7645801 | MYLAN SPECIALITY LP | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
Jul, 2027
(3 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 24 December, 1987
Treatment: NA
Dosage: ENEMA;RECTAL
SFROWASA family patents
12. Tobi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5508269 | MYLAN SPECIALITY LP | Aminoglycoside formulation for aerosolization |
Oct, 2014
(9 years ago) | |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 December, 1997
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: SOLUTION;INHALATION
TOBI family patents
13. Tobi Podhaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7097827 | MYLAN SPECIALITY LP | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
Apr, 2016
(8 years ago) | |
| US8349294 | MYLAN SPECIALITY LP | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
May, 2020
(3 years ago) | |
| US7442388 | MYLAN SPECIALITY LP | Phospholipid-based powders for drug delivery |
May, 2020
(3 years ago) | |
| US7368102 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycosides |
Dec, 2022
(1 year, 4 months ago) | |
| US8715623 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(1 year, 4 months ago) | |
| US9421166 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(1 year, 4 months ago) | |
| US7516741 | MYLAN SPECIALITY LP | Aerosolization apparatus with feedback mechanism |
Jan, 2024
(3 months ago) | |
| USRE47526 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Apr, 2024
(14 days ago) | |
| US8069851 | MYLAN SPECIALITY LP | Aeorosolization apparatus with air inlet shield |
Sep, 2024
(5 months from now) | |
| US11484671 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2024
(6 months from now) | |
| US8664187 | MYLAN SPECIALITY LP | Methods of treatment of endobronchial infections |
Jun, 2025
(1 year, 1 month from now) | |
| US7559325 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Oct, 2025
(1 year, 6 months from now) | |
| US8869794 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncturing member |
Sep, 2028
(4 years from now) | |
| US10207066 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER;INHALATION
TOBI PODHALER family patents